Office of the Director, National Institutes of Health; Notice of Meeting, 41914-41915 [E9-19906]
Download as PDF
41914
Federal Register / Vol. 74, No. 159 / Wednesday, August 19, 2009 / Notices
beginning in the fall, 2009, with funding
to commence in spring, 2010. Interested
parties may sign up to receive updates
about AHRQ’s Effective Health Care
Program at https://
effectivehealthcare.ahrq.gov/.
ADDRESSES: The future CER solicitations
will be published in the NIH Guide:
https://grants.nih.gov/grants/guide/
index.html.
FOR FURTHER INFORMATION CONTACT:
Until the solicitations are published,
AHRQ cannot provide information on
their contents.
Direct any general comments
regarding the Effective Health Care
program to: Lia Hotchkiss, MPH, PMP,
Center for Outcomes and Evidence,
Agency for Healthcare Research and
Quality, 540 Gaither Road, Rockville,
MD 20850, Telephone: 301–427–1502,
E-mail address:
Effectivehealthcare@ahrq.hhs.gov.
SUPPLEMENTARY INFORMATION:
jlentini on DSKJ8SOYB1PROD with NOTICES
Background
The Agency for Healthcare Research
and Quality (AHRQ) has been
supporting comparative effectiveness
research for many years and since 2005
through AHRQ’s Effective Health Care
Program, which was authorized under
Section 1013 of the Medicare
Prescription Drug, Improvement, and
Modernization Act of 2003. The
Effective Health Care program provides
systematic reviews and develops other
translational information and tools
designed to inform health care decision
making. The Effective Health Care
Program advances the methodology of
comparative effectiveness research
(CER) and provides training grants to
enhance the pool of researchers who can
perform CER.
Comparative Effectiveness Research
Initiative Description
Funding Opportunity
Announcements soliciting research
grant applications for CER will provide
$148 million for evidence generation.
This includes $100 million for the
Clinical and Health Outcomes Initiative
in Comparative Effectiveness (CHOICE),
a new, coordinated, national effort to
establish a series of prospective
pragmatic clinical comparative
effectiveness studies that measure the
benefits treatments produce in routine
clinical practice and will include novel
study designs focusing on real-world
and under-represented populations
(children, elderly, racial and ethnic
minorities, and other understudied
populations), and $48 million for the
establishment or enhancement of
national patient registries that can be
VerDate Nov<24>2008
16:53 Aug 18, 2009
Jkt 217001
used for researching the longitudinal
effects of different interventions and
collecting data on under-represented
populations. Additional grant funding is
expected to include $29.5 million to
support innovative translation and
dissemination grants related to CER, as
well as $20 million to support training
and career development in CER.
Requests for Contracts for CER will
provide $9.5 million to establish an
infrastructure to identify new and/or
emerging issues for comparative
effectiveness review investments. Also,
$10 million will establish a Citizen’s
Forum to formally engage all
stakeholders, and to expand and
standardize public involvement in the
entire Effective Health Care enterprise.
Additionally, AHRQ anticipates
supporting other grants ($1 million) and
enhancing existing contracts for
evidence synthesis ($50 million),
evidence generation ($24 million),
translation and dissemination ($5
million), and salary and benefits for
ARRA-related full-time equivalent
positions ($3 million).
Place: Bethesda Marriott Suites, 6711
Democracy Boulevard, Bethesda, MD 20817.
Contact Person: D. G. Patel, PhD, Scientific
Review Officer, Review Branch, DEA,
NIDDK, National Institutes of Health, Room
756, 6707 Democracy Boulevard, Bethesda,
MD 20892–5452, (301) 594–7682,
pateldg@niddk.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: August 11, 2009.
Carolyn M. Clancy,
AHRQ, Director.
[FR Doc. E9–19758 Filed 8–18–09; 8:45 am]
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the
Recombinant DNA Advisory Committee.
The meeting will be open to the
public, with attendance limited to space
available. Individuals who plan to
attend and need special assistance, such
as sign language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
BILLING CODE 4160–90–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; P01 Application.
Date: October 28, 2009.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
Dated: August 11, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–19889 Filed 8–18–09; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Office of the Director, National
Institutes of Health; Notice of Meeting
Name of Committee: Recombinant DNA
Advisory Committee.
Date: September 9–10, 2009.
Time: September 9, 2009, 1:15 p.m. to 5:45
p.m.
Agenda: The Recombinant DNA Advisory
Committee will review and discuss selected
human gene transfer protocols as well as
related data management activities. Please
check the meeting agenda at https://
oba.od.nih.gov/rdna/rdna.html for more
information.
Place: Hilton Washington/Rockville, 1750
Rockville Pike, Rockville, MD 20852.
Time: September 10, 2009, 8:30 a.m. to 11
a.m.
Agenda: The Recombinant DNA Advisory
Committee will review and discuss selected
human gene transfer protocols as well as
related data management activities. Please
check the meeting agenda at https://
oba.od.nih.gov/rdna/rdna.html for more
information.
Place: Hilton Washington/Rockville, 1750
Rockville Pike, Rockville, MD 20852.
Contact Person: Laurie Lewallen, Advisory
Committee Coordinator, Office of
Biotechnology Activities, National Institutes
of Health, 6705 Rockledge Drive, Room 750,
E:\FR\FM\19AUN1.SGM
19AUN1
Federal Register / Vol. 74, No. 159 / Wednesday, August 19, 2009 / Notices
Bethesda, MD 20892–7985. 301–496–9838.
lewallla@od.nih.gov.
Information is also available on the
Institute’s/Center’s home page: https://
oba.od.nih.gov/rdna/rdna.html, where an
agenda and any additional information for
the meeting will be posted when available.
OMB’s ‘‘Mandatory Information
Requirements for Federal Assistance Program
Announcements’’ (45 FR 39592, June 11,
1980) requires a statement concerning the
official government programs contained in
the Catalog of Federal Domestic Assistance.
Normally NIH lists in its announcements the
number and title of affected individual
programs for the guidance of the public.
Because the guidance in this notice covers
virtually every NIH and Federal research
program in which DNA recombinant
molecule techniques could be used, it has
been determined not to be cost effective or
in the public interest to attempt to list these
programs. Such a list would likely require
several additional pages. In addition, NIH
could not be certain that every Federal
program would be included as many Federal
agencies, as well as private organizations,
both national and international, have elected
to follow the NIH Guidelines. In lieu of the
individual program listing, NIH invites
readers to direct questions to the information
address above about whether individual
programs listed in the Catalog of Federal
Domestic Assistance are affected.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.14, Intramural Research
Training Award; 93.22, Clinical Research
Loan Repayment Program for Individuals
from Disadvantaged Backgrounds; 93.232,
Loan Repayment Program for Research
Generally; 93.39, Academic Research
Enhancement Award; 93.936, NIH Acquired
Immunodeficiency Syndrome Research Loan
Repayment Program; 93.187, Undergraduate
Scholarship Program for Individuals from
Disadvantaged Backgrounds, National
Institutes of Health, HHS)
Dated: August 11, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–19906 Filed 8–18–09; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
jlentini on DSKJ8SOYB1PROD with NOTICES
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
VerDate Nov<24>2008
16:53 Aug 18, 2009
Jkt 217001
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review, Special Emphasis Panel. RFA–OD–
09–003 Challenge Grants Panel 30.
Date: July 28, 2009.
Time: 11 a.m. to 2 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Cathy Wedeen, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3213,
MSC 7808, Bethesda, MD 20892. 301–435–
1191. wedeenc@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific
Review, Special Emphasis Panel. RFA–OD–
09–003 Challenge Grants Panel 31.
Date: August 3, 2009.
Time: 11 a.m. to 1 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: George W. Chacko, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5170,
MSC 7849, Bethesda, MD 20892. 301–435–
1245. chackoge@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific
Review, Special Emphasis Panel. RFA–OD–
09–003 Challenge Grants Panel 32.
Date: August 7, 2009.
Time: 2:45 p.m. to 3:15 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Maribeth Champoux, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3170,
MSC 7848, Bethesda, MD 20892. 301–594–
3163. champoum@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific
Review, Special Emphasis Panel. RFA–OD–
09–003 Challenge Grant Panel 33.
Date: August 11, 2009.
Time: 1 p.m. to 3 p.m.
Agenda: To review and evaluate grant
applications.
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
41915
Place: National Institute of Health,
Bethesda, MD 20892 (Telephone Conference
Call).
Contact Person: John Firrell, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5213,
MSC 7854, Bethesda, MD 20892. 301–435–
2598. firrellj@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific
Review, Special Emphasis Panel. RFA–OD–
09–003 Challenge Grants Panel 34.
Date: August 12, 2009.
Time: 3 p.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Bob Weller, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3160,
MSC 7770, Bethesda, MD 20892. (301) 435–
0694. wellerr@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific
Review, Special Emphasis Panel. RFA–OD–
09–003 Challenge Grants Panel 35.
Date: August 13, 2009.
Time: 3 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Noni Byrnes, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5130,
MSC 7840, Bethesda, MD 20892. (301) 435–
1023. byrnesn@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific
Review, Special Emphasis Panel. RFA OD–
09–003 Challenge Grants Panel 36.
Date: August 14, 2009.
Time: 1 p.m. to 2 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Carole L. Jelsema, PhD,
Chief and Scientific Review Officer, Center
for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4176,
MSC 7850, Bethesda, MD 20892. (301) 435–
1248. jelsemac@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
E:\FR\FM\19AUN1.SGM
19AUN1
Agencies
[Federal Register Volume 74, Number 159 (Wednesday, August 19, 2009)]
[Notices]
[Pages 41914-41915]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-19906]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Office of the Director, National Institutes of Health; Notice of
Meeting
Pursuant to section 10(a) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of a meeting of the
Recombinant DNA Advisory Committee.
The meeting will be open to the public, with attendance limited to
space available. Individuals who plan to attend and need special
assistance, such as sign language interpretation or other reasonable
accommodations, should notify the Contact Person listed below in
advance of the meeting.
Name of Committee: Recombinant DNA Advisory Committee.
Date: September 9-10, 2009.
Time: September 9, 2009, 1:15 p.m. to 5:45 p.m.
Agenda: The Recombinant DNA Advisory Committee will review and
discuss selected human gene transfer protocols as well as related
data management activities. Please check the meeting agenda at
https://oba.od.nih.gov/rdna/rdna.html for more information.
Place: Hilton Washington/Rockville, 1750 Rockville Pike,
Rockville, MD 20852.
Time: September 10, 2009, 8:30 a.m. to 11 a.m.
Agenda: The Recombinant DNA Advisory Committee will review and
discuss selected human gene transfer protocols as well as related
data management activities. Please check the meeting agenda at
https://oba.od.nih.gov/rdna/rdna.html for more information.
Place: Hilton Washington/Rockville, 1750 Rockville Pike,
Rockville, MD 20852.
Contact Person: Laurie Lewallen, Advisory Committee Coordinator,
Office of Biotechnology Activities, National Institutes of Health,
6705 Rockledge Drive, Room 750,
[[Page 41915]]
Bethesda, MD 20892-7985. 301-496-9838. lewallla@od.nih.gov.
Information is also available on the Institute's/Center's home
page: https://oba.od.nih.gov/rdna/rdna.html, where an agenda and any
additional information for the meeting will be posted when
available.
OMB's ``Mandatory Information Requirements for Federal
Assistance Program Announcements'' (45 FR 39592, June 11, 1980)
requires a statement concerning the official government programs
contained in the Catalog of Federal Domestic Assistance. Normally
NIH lists in its announcements the number and title of affected
individual programs for the guidance of the public. Because the
guidance in this notice covers virtually every NIH and Federal
research program in which DNA recombinant molecule techniques could
be used, it has been determined not to be cost effective or in the
public interest to attempt to list these programs. Such a list would
likely require several additional pages. In addition, NIH could not
be certain that every Federal program would be included as many
Federal agencies, as well as private organizations, both national
and international, have elected to follow the NIH Guidelines. In
lieu of the individual program listing, NIH invites readers to
direct questions to the information address above about whether
individual programs listed in the Catalog of Federal Domestic
Assistance are affected.
(Catalogue of Federal Domestic Assistance Program Nos. 93.14,
Intramural Research Training Award; 93.22, Clinical Research Loan
Repayment Program for Individuals from Disadvantaged Backgrounds;
93.232, Loan Repayment Program for Research Generally; 93.39,
Academic Research Enhancement Award; 93.936, NIH Acquired
Immunodeficiency Syndrome Research Loan Repayment Program; 93.187,
Undergraduate Scholarship Program for Individuals from Disadvantaged
Backgrounds, National Institutes of Health, HHS)
Dated: August 11, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. E9-19906 Filed 8-18-09; 8:45 am]
BILLING CODE 4140-01-P